Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk

Journal of Investigative Dermatology

Volumn 131, Issue 5, 2011, Pages 1159-1166

  Stern, Robert S ^a,b   Huibregtse, Annemieke ^a,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PSORALEN; URIC ACID;

ADULT; ARTICLE; CANCER MORTALITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; LEUKOCYTE COUNT; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PHOTOTHERAPY; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; SYSTEMIC THERAPY; ULTRAVIOLET A RADIATION;

EID: 79954654812     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.399     Document Type: Article

References (53)

1. Akhyani M, Ehsani AH, Robati RM et al. (2007) The lipid profile in psoriasis: a controlled study. J Eur Acad Dermatol Venereol 21:1330-2 (Pubitemid 350020138)
2. Balci DD, Balci A, Karazincir S et al. (2009) Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol 23:1-6
3. Brauchli YB, Jick SS, Miret M et al. (2009) Psoriasis and risk of incident cancer: an inception cohort study with a nested case-control analysis. J Invest Dermatol 129:2604-12
4. CDCa (Centers for Disease Control and Prevention) CDC Wonder: Compressed Mortality File Archives. http://wonder.cdc.gov/mortarchives.html (accessed Spring 2008)
5. CDCb (Centers for Disease Control and Prevention) CDC Wonder: About Compressed Mortality, 1979-1998. http://wonder.cdc.gov/cmf-icd9.html (accessed 20 February, 2009)
6. Cleaves MA, Gould WM, Gutierrez RG et al. (2008) An Introduction to Survival Analysis Using Stata. 2nd edn. Stata Press: Texas, 372
7. Clinical Trials.gov. Effects of TNF-alpha antagonism (etanercept) in patients with the metabolic syndrome and psoriasis. http://clinicaltrials.gov/ ct2/show/NCT00477191?term=metabolic+syndrome+psoriasis&rank=2 (accessed 5 May 2009)
8. Doody MM, Hayes HM, Bilgrad R (2001) Comparability of national death index plus and standard procedures for determining causes of death in epidemiologic studies. Ann Epidemiol 11:46-50 (Pubitemid 32054787)
9. Fang J, Alderman MH (2000) Serum uric acid and cardiovascular mortality. The NHANES epidemiologic follow-up study, 1971-1992. JAMA 283:2404-10 (Pubitemid 30257539)
10. Federman DG, Shelling M, Prodanovich S et al. (2009) Psoriasis: an opportunity to identify cardiovascular risk. Br J Dermatol 160:1-7
11. Fiscella K, Tancredi D (2008) Socioeconomic status and coronary heart disease risk prediction. JAMA 300:2666-8
12. Fridewald VE, Cather JC, Gelfand JM et al. (2008) AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol 102:1631-43
13. Gelfand JM, Neimann AL, Shin DB et al. (2006) Risk of myocardial infarction in patients with psoriasis. JAMA 296:1735-41 (Pubitemid 44547793)
14. Gelfand JM, Troxel AB, Lewis JD et al. (2007) The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 143:1293-9
15. Gerdes S, Zahl VA, Knopf H et al. (2008) Comedication related to comorbities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol 159:1116-23
16. Gillum RF, Mussolino ME, Madans JH (2005) Counts of neutrophils, lymphocytes and monocytes, cause-specific mortality and coronary heart disease: the NHANES-I epidemiologic follow-up study. Ann Epidemiol 15:266-71 (Pubitemid 40386500)
17. Hammad TA, McAdams MA, Feight A et al. (2008) Determining the predictive value of Read/OXMIS codes to identify acute myocardial infarction in the general practice research database. Pharmacoepidemiol Drug Saf 17:1197-201
18. Hendershot GE (1988) Health of the foreign-born population: United States, 1985-1986. Adv Data 157:1-6
19. Huerta C, Rivero E, Garcia Rodriguez LA (2007) Incidence and risk factors for psoriasis in the general population. Arch Dermatol 143:1559-65 (Pubitemid 350277774)
20. Kaye JA, Li L, Jick SS (2008) Incidence of risk factors for myocardial infarction and other vascular diseases in patients with psoriasis. Br J Dermatol 159:895-902
21. Kimball AB, Gladman D, Gelfand JM et al. (2008a) National psoriasis foundation clinical consensus on psoriasis comorbidities and recom-mendations for screening. J Am Acad Dermatol 58:1031-42
22. Kimball AB, Robinson D, Wu Y et al. (2008b) Cardiovascular diseaseand risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology 217:27-37 (Pubitemid 351896565)
23. Kurd SK, Gelfand JM (2008) The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol 60:218-24
24. Leonardi CL, Kimball AB, Papp KA et al. (2008) Efficacy and safety ustebinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial. Lancet371:1665-74 (Pubitemid 351671883)
25. Ludwig RJ, Herzog C, Rostock A et al. (2007) Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 156:271-6 (Pubitemid 46095954)
26. Lunn M, McNeil D (1995) Applying Cox regression to competing risks. Biometrics 51:524-32
27. McGee D, Cooper R, Liao Y et al. (1996) Patterns of comorbidity and mortality risk in blacks and whites. Ann Epidemiol 6:381-5 (Pubitemid 26375173)
28. Melerba M, Gisondi P, Radaeli A et al. (2006) Plasma homocysteine and folate levels in patients with chronic plaque type psoriasis. Br J Dermatol 155:1165-9 (Pubitemid 44729990)
29. Melski JW, Tanenbaum L, Parrish JA et al. (1977) Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol 68:328-35 (Pubitemid 8132292)
30. NCHSa (National Center for Health Statistics) National Vital Statistics System. Prevalence of BMI 25+ by age, sex, and survey. http://www.cdc.gov/nchs/ data/nhanes/overweight.pdf (accessed 29 January 2008)
31. NCHSb (National Center for Health Statistics) National Death Index Users Guide. http://www.cdc.gov/nchs/data-access/ndi/ndi-user-guide.htm (accessed 2 February 2009)
32. NCHSc (National Center for Health Statistics) National Death Index Facts and Figures, 2008. http://www.cdc.gov/nchs/data/dvs/2a2008Final.pdf (accessed January and February 2008)
33. NCHSd (National Center for Health Statistics) ICD-9-CM Official Guide-lines for Coding and Reporting. http://www.cdc.gov/nchs/data/icd9/ icdguide09.pdf (accessed 22 February 2009)
34. NCHSe (National Center for Health Statistics) Death rates by 10-year age groups and age-adjusted death rates for 113 selected causes, race, and sex: United States, 1979-98. http://www.cdc.gov/nchs/data/statab/hist001r.pdf (accessed December 2007, January 2008, and February 2008)
35. NCHSf (National Center for Health Statistics) Vital Statistics Data Available Online. http://www.cdc.gov/nchs/data-access/Vitalstatsonline. htm#Mortality-Multiple (accessed December 2007, January 2008, and February 2008)
36. NDI. National Death Index Plus: Coded Causes of Death Supplement to the National Death Index User's Manual. National Center for Health Statistics: Hyattsville, MD, 2005
37. Neimann AL, Shin DB, Wang X et al. (2006) Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 55:829-35 (Pubitemid 44556851)
38. Ohtsuka T (2008) The relation between high-sensitivity C-reactive protein and maximum body mass index in patients with psoriasis. Br J Dermatol 158:1134-73
39. Parrish JA, Fitzpatrick TB, Tanenbaum L et al. (1974) Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med291:1207-11
40. Prodanovich S, Ma F, Taylor JR et al. (2005) Methotrexate reduces the incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 52:262-7
41. Reynoso-von Drateln C, Martinez-Abdunis E, Balcázar-Munoz BR et al. (2003) Lipid, profile, insulin secretion, and insulin sensitivity in psoriasis. J Am Acad Dermatol 48:822-5
42. Rocha-Pereira P, Santos-Silva A, Rebelo I et al. (2001) Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 303:33-9 (Pubitemid 32121803)
43. Shapiro J, Cohen AD, David M et al. (2007) The association between psoriasis, diabetes mellitus and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 56:629-34 (Pubitemid 46400186)
44. Späh F (2008) Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach. Br J Dermatol 159:10-7
45. Stern RS, Laird N, Melski J et al. (1984) Cutaneous squamous-cell carcinoma in patients treated with PUVA. N Engl J Med 310:11 56-61
46. Stern RS, Nichols KT, Väkevä LH (1997) Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet-a radiation (PUVA). The PUVA follow-up study. N Engl J Med336:1041-5 (Pubitemid 27163855)
47. Stern RS, Nijsten T, Feldman SR et al. (2004) Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Invest Dermatol 9:136-9 (Pubitemid 38457271)
48. Sterry W, Strober BE, Menter A (2007) Obesity in psoriasis: the metabolic, clinical and therapeutic implications. Report of an interdisciplinary conference and review. Br J Dermatol 157:649-55 (Pubitemid 47389868)
49. Strober B, Teller C, Yamauchi P et al. (2008) Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 159:322-30 (Pubitemid 352009830)
50. TDRdata.com. ICD-9 and-10 Translation Tools. http://www.tdrdata.com/IPD/ ipd-ICDTranslator.aspx (accessed 26 May 2009)
51. Von Elm E, Altman DG, Egger M et al. (2007) The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet370:1453-7
52. Wakkee M, Herings RMC, Nijsten T (2010) Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort. J Invest Dermatol 130:962-7
53. Wakkee M, Thio HB, Prens EP et al. (2007) Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. Artherosclerosis 190:1-9 (Pubitemid 44908334)